Literature DB >> 24054860

Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL).

Krystyna Mazan-Mamczarz1, Ronald B Gartenhaus.   

Abstract

MicroRNAs (miRNAs) are small endogenous RNA molecules that regulate gene expression at the post-transcriptional level through its sequence complementation with target mRNAs. An individual miRNA species can simultaneously influence the expression of multiple genes and conversely, several miRNAs can synchronously control expression of specific gene product mRNA levels. Thus, miRNAs expression in cells has to be precisely regulated and alterations in miRNA levels may cause an aberrant expression of genes involved in oncogenic pathways and consequently result in cancer development. Indeed, miRNA expression is often deregulated in many cancers, including B-cell lymphomas. Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of B-cell lymphomas with different genetic backgrounds, morphologic features, and responses to therapy. Over the past decade, miRNAs emerged as a new tool for understanding DLBCL biology, and promising candidate molecular markers in DLBCL classification and treatment. In this review, we will focus on miRNAs aberrantly expressed in DLBCL and discuss the putative mechanisms of this deregulation. Additionally, we will summarize miRNAs' involvement in the identification of DLBCL subgroups, and their potential role as diagnostic/prognostic biomarkers as well as specific therapeutic targets for DLBCL.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  DLBCL; Lymphoma; Microrna

Mesh:

Substances:

Year:  2013        PMID: 24054860      PMCID: PMC3856880          DOI: 10.1016/j.leukres.2013.08.020

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  127 in total

1.  Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo.

Authors:  V J Craig; A Tzankov; M Flori; C A Schmid; A G Bader; A Müller
Journal:  Leukemia       Date:  2012-04-23       Impact factor: 11.528

Review 2.  The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas.

Authors:  Lorena Di Lisio; Nerea Martinez; Santiago Montes-Moreno; Miguel Piris-Villaespesa; Margarita Sanchez-Beato; Miguel A Piris
Journal:  Blood       Date:  2012-07-03       Impact factor: 22.113

3.  A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.

Authors:  Rachel E Culpin; Stephen J Proctor; Brian Angus; Stephen Crosier; John J Anderson; Tryfonia Mainou-Fowler
Journal:  Int J Oncol       Date:  2010-08       Impact factor: 5.650

4.  Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis: a preliminary study.

Authors:  Jing Wu; Chanyi Lu; Ni Diao; Shu Zhang; Sen Wang; Feifei Wang; Yan Gao; Jiazhen Chen; Lingyun Shao; Jingning Lu; Xuelian Zhang; Xinhua Weng; Honghai Wang; Wenhong Zhang; Yuxian Huang
Journal:  Hum Immunol       Date:  2011-10-14       Impact factor: 2.850

5.  MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.

Authors:  Haitao Bai; Ju Wei; Chong Deng; Xiaoyu Yang; Chun Wang; Rang Xu
Journal:  Int J Hematol       Date:  2012-12-30       Impact factor: 2.490

6.  miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells.

Authors:  Haibo Zhou; Xinfang Huang; Huijuan Cui; Xiaobing Luo; Yuanjia Tang; Shunle Chen; Li Wu; Nan Shen
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.

Authors:  Raquel Malumbres; Kristopher A Sarosiek; Elena Cubedo; Jose W Ruiz; Xiaoyu Jiang; Randy D Gascoyne; Robert Tibshirani; Izidore S Lossos
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

9.  Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Authors:  Cheng Li; Sang-Woo Kim; Deepak Rai; Aswani R Bolla; Siddharth Adhvaryu; Marsha C Kinney; Ryan S Robetorye; Ricardo C T Aguiar
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

10.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

View more
  29 in total

1.  MicroRNA-21 regulates the viability and apoptosis of diffuse large B-cell lymphoma cells by upregulating B cell lymphoma-2.

Authors:  Ke Liu; Jingxia Du; Linhai Ruan
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

Review 2.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

3.  Novel MicroRNA signatures in HPV-mediated cervical carcinogenesis in Indian women.

Authors:  Shweta Sharma; Showket Hussain; Kartik Soni; Pallavi Singhal; Richa Tripathi; V G Ramachandran; Sonal Sharma; Shukla Das; Beena Pillai; Mausumi Bharadwaj
Journal:  Tumour Biol       Date:  2015-10-27

4.  Effects of miR‑210‑3p on the erythroid differentiation of K562 cells under hypoxia.

Authors:  Caiyan Hu; Yupeng Yan; Chengbing Fu; Jin Ding; Tiantian Li; Shuqiong Wang; Liu Fang
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

Review 5.  MicroRNAs as potential biomarkers in cancer: opportunities and challenges.

Authors:  Huiyin Lan; Haiqi Lu; Xian Wang; Hongchuan Jin
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

6.  MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.

Authors:  Heounjeong Go; Ji-Young Jang; Pil-Jong Kim; Young-Goo Kim; Soo Jeong Nam; Jin Ho Paik; Tae Min Kim; Dae Seog Heo; Chul-Woo Kim; Yoon Kyung Jeon
Journal:  Oncotarget       Date:  2015-06-20

7.  A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma.

Authors:  Afshin Beheshti; Charles Vanderburg; J Tyson McDonald; Charusheila Ramkumar; Tatenda Kadungure; Hong Zhang; Ronald B Gartenhaus; Andrew M Evens
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

Review 8.  miRNA-Mediated Control of B Cell Responses in Immunity and SLE.

Authors:  Stephanie L Schell; Ziaur S M Rahman
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

9.  Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo.

Authors:  Eleni Anastasiadou; Anita G Seto; Xuan Beatty; Melanie Hermreck; Maud-Emmanuelle Gilles; Dina Stroopinsky; Lauren C Pinter-Brown; Linda Pestano; Cinzia Marchese; David Avigan; Pankaj Trivedi; Diana M Escolar; Aimee L Jackson; Frank J Slack
Journal:  Clin Cancer Res       Date:  2020-11-18       Impact factor: 13.801

10.  Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development.

Authors:  Krystyna Mazan-Mamczarz; X Frank Zhao; Bojie Dai; James J Steinhardt; Raymond J Peroutka; Kimberly L Berk; Ari L Landon; Mariola Sadowska; Yongqing Zhang; Elin Lehrmann; Kevin G Becker; Rita Shaknovich; Zhenqiu Liu; Ronald B Gartenhaus
Journal:  PLoS Genet       Date:  2014-01-30       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.